Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofetabart Mipitecan (LY4170156) in Advanced Solid Tumors
NCT06400472Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2024
- Primary completion
- Jun 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 7
01
Overview
Phase 1, open-label trial of sofetabart mipitecan in ovarian cancer, endometrial cancer (EC), Cervical Cancer (CC) and 4 more (11 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Recommended Phase 2 Dose, Overall Response Rate and 1 more. Started May 2024; status: recruiting.
02
Drugs
sofetabart mipitecan
03
Conditions
ovarian cancerendometrial cancer (EC)Cervical Cancer (CC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06400472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400472.